Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892134 | 0.94 | TAAR1 (0.53) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892144 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892140 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892230 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892135 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892223 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892136 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892231 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892225 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL11892220 | 0.92 | TAAR1 (0.52) | TAAR1TSHRPTGS1PTGS2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10334851-B2 | Herbicidal isoxazolo[5,4-B]pyridines | BASF SE (DE) | 2019-07-02 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20170367340-A1 | Herbicidal Isoxazolo[5,4-B]pyridines | BASF SE (DE) | 2017-12-28 | — | — | US | disclosed |
| US-9609870-B2 | Herbicidal isoxazolo[5,4-b]pyridines | BASF SE (DE) | 2017-04-04 | — | — | US | disclosed |
| US-9609870-B2 | Herbicidal isoxazolo[5,4-b]pyridines | BASF SE (DE) | 2017-04-04 | — | — | US | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20160037777-A1 | Herbicidal Isoxazolo[5,4-B]pyridines | BASF SE (DE) | 2016-02-11 | — | — | US | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-03-17 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | TAAR1 1045/4885TSHR 2926/4885PTGS1 807/4885 |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | TAAR1 136/4885TSHR 238/4885PTGS1 1502/4885 |
| US-10334851-B2 | Herbicidal isoxazolo[5,4-B]pyridines | CYP4X1, PNPO, PRDX4 | TAAR1 3512/4885TSHR 2393/4885PTGS1 1672/4885 |
| US-20160037777-A1 | Herbicidal Isoxazolo[5,4-B]pyridines | CYP4X1, PNPO, PRDX4 | TAAR1 3512/4885TSHR 2393/4885PTGS1 1672/4885 |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | TAAR1 1045/4885TSHR 2926/4885PTGS1 807/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | TAAR1 449/4885TSHR 4136/4885PTGS1 1041/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | TAAR1 494/4885TSHR 3769/4885PTGS1 887/4885 |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | TAAR1 1045/4885TSHR 2926/4885PTGS1 807/4885 |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | INSR, ACACA, IAPP | TAAR1 1045/4885TSHR 2926/4885PTGS1 807/4885 |
| US-20170367340-A1 | Herbicidal Isoxazolo[5,4-B]pyridines | CYP4X1, PNPO, PRDX4 | TAAR1 3512/4885TSHR 2393/4885PTGS1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.